BioCentury | Jan 4, 2020
Company News

Next act for BeiGene’s tislelizumab: a Leap deal for gastric cancer

...Novartis AG (NYSE:NVS; SIX:NOVN) have the only other DKK1 inhibitor in the clinic. The partners’ BHQ880...
BioCentury | Feb 25, 2016
Distillery Therapeutics

Therapeutics: Dickkopf homolog 1 (DKK1)

...in models of other diseases involving Th2 inflammatory responses. Novartis AG and MorphoSys AG have BHQ880...
BioCentury | Jun 20, 2013
Distillery Therapeutics

Indication: Cardiovascular disease

...effect of Dkk1 deficiency in mouse models for atherosclerosis. Novartis AG and MorphoSys AG have BHQ880...
BioCentury | Dec 8, 2011
Distillery Therapeutics

Indication: Cancer

...with control vector injection. Next steps include running a Phase I trial in MM patients. BHQ880...
BioCentury | Feb 28, 2011
Company News

MorphoSys, Novartis deal

...said five antibody programs under the deal are currently in clinical testing, including lead compound BHQ880...
BioCentury | Jul 13, 2009
Company News

MorphoSys, Novartis deal

...advanced two HuCAL compounds to the clinic: an undisclosed compound in Phase I testing; and BHQ880...
BioCentury | Jul 7, 2009
Company News

MorphoSys, Novartis deal to run through 2017

...advanced two HuCAL compounds to the clinic: an undisclosed compound in Phase I testing; and BHQ880...
Items per page:
1 - 7 of 7